| Literature DB >> 35600312 |
Rosa Sessa1, Emanuela Anastasi2, Gabriella Brandolino3, Roberto Brunelli3, Marisa Di Pietro1, Simone Filardo1, Luisa Masciullo3, Gianluca Terrin3, Maria Federica Viscardi3, Maria Grazia Porpora3.
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2) represents an emerging infection that is spreading around the world. Among susceptible patients, pregnant women are more likely to develop serious complications and negative obstetric outcomes. Vertical transmission constitutes a debating issue which has not been completely understood. This review aims at describing the currently available evidence on SARS-CoV2 vertical transmission. We carried out a computerized literature search in the Cochrane Library, PubMed, Scopus and Web of Science, selecting the most relevant studies on vertical transmission from the outbreak onset until February 2022. The analysis of the available literature identifies the presence of SARS-CoV2 genome in different biological specimens, confirming the hypothesis that a transplacental infection can occur. In spite of the high number of infected people around the world, mother-to-child infections have been infrequently reported but it can be observed under certain biologic conditions. A deep knowledge of the underlying mechanisms of SARS-CoV2 vertical transmission is of paramount importance for planning an adequate management for the affected mothers and newborns.Entities:
Keywords: SARS-CoV-2; coronavirus; neonatal infection; placenta; pregnancy; pregnancy outcomes; vertical transmission
Year: 2022 PMID: 35600312 PMCID: PMC9117645 DOI: 10.3389/fphys.2022.875806
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.755
Pregnancy outcomes associated to SARS-CoV-2 infection and respective incidence.
| Fetal malformations |
| 0.5% |
| Preterm Birth |
| 12.6% |
|
| 18.8% | |
|
| 16.7% | |
|
| 17.6% | |
|
| 16.9% | |
|
| 16% | |
|
| 7.19% | |
| IUGR |
| 11.7% |
|
| 1.9% | |
| Hypertensive disorders |
| 7.74% |
|
| 12% | |
|
| 18.8% | |
|
| 8.84% | |
| Gestational diabetes |
| 11% |
|
| 7.8% | |
|
| 6.5% | |
| Miscarriages |
| 12.5% |
|
| 2.2% | |
| Stillbirths |
| 0.8% |
|
| 0.5% |
FIGURE 1Schematic representation of ACE 2 and its co-receptor, TMPRSS 2, distribution through trimesters and trophoblast layers, and the potential adhesion and invasion pathways of SARS-CoV-2. In the first trimester, ACE2 is preferentially expressed in the syncytiotrophoblast layer, while TMPRSS2 is mostly localized on the cytotrophoblast and extravillous trophoblast layers; in the second and third trimesters, ACE2 is also expressed on the extravillous trophoblast layer, and TMPRSS2 can be found on all trophoblast sites.
Studies on the vertical transmission of Sars-CoV-2. CR, case report; OS, observational study; PCS, prospective cohort study; RS, retrospective study; CaS, case series; VD, vaginal delivery; CS, cesarean section.
| Author year | Type of study | n. patients | n. newborns | Gestational age (weeks + days) | Mode of delivery (n.) | Neonatal swab n. | Placenta n. | Cord blood n. | Amniotic fluid n. | Neonatal sierology n. |
|---|---|---|---|---|---|---|---|---|---|---|
|
| CR | 1 | 1 | 33 | CS (1) | 1/1 | - | - | - | IgG 0/1 |
|
| CR | 1 | 1 | 19 | VD (1) | 0/1 | 1/1 | - | 0/1 | - |
|
| CR | 1 | 1 | 28 | CS (1) | 0/1 | - | - | - | IgG 0/1 |
|
| OS | 7 | 2 | 8-37+3 | CS (2) | 0/2 | 1/2 | 1/2 | 0/7 | IgG 1/1 |
|
| RS | 3 | 3 | 35– 38+6 | CS (3) | 0/3 | - | - | - | - |
|
| CR | 1 | 1 | 34+2 | CS (1) | 0/1 | - | - | - | IgG 1/1 |
|
| RS | 42 | 42 | <37 - >37 | VD (24) | 3/42 | - | - | - | - |
|
| CR | 1 | 2 | 36 | CS (1) | 0/2 | - | - | - | - |
|
| CaS | 9 | 9 | 27-39 | VD (1) | 1/9 | 0/9 | - | 0/9 | - |
|
| CaS | 7 | 7 | 37-40 | VD (1) | 1/7 | - | - | 0/7 | - |
|
| CR | 1 | 1 | 35+3 | CS (1) | 0/1 | 0/1 | 0/1 | - | - |
|
| CaS | 17 | 17 | 35-41 | CS (17) | 2/17 | - | - | - | - |
|
| CR | 1 | 1 | 35 | CS (1) | 1/1 | 1/1 | 0/1 | - | - |
|
| PCS | 427 | 244 | <22 – 37+6 | VD (101) | 12/244 | - | - | - | - |
|
| CR | 1 | 1 | 35+2 | CS (1) | 0/1 | 0/1 | 0/1 | 0/1 | - |
|
| CR | 1 | 1 | 36+2 | CS (1) | 0/1 | 0/1 | 0/1 | 0/1 | - |
|
| CaS | 3 | 3 | 37-40 | VD (1) | 0/3 | - | 0/3 | - | - |
|
| CR | 1 | 1 | 40+3 | VD (1) | 0/1 | - | - | - | - |
|
| CR | 1 | 1 | 39+4 | CS (1) | 0/1 | - | - | - | - |
|
| CaS | 22 | 22 | 35-37 | VD (11) | 2/22 | - | - | - | - |
|
| CaS | 31 | 11 | 26+4 – 41+2 | VD (7) | 0/10 | 1/1 | - | - | - |
|
| PCS | 64 | 33 | 16+1 – 39+1 | VD (8) | 1/33 | - | - | - | |
|
| RS | 28 | 23 | 36+5 – 39 | VD (5) | 0/23 | - | - | - | - |
|
| CR | 1 | 1 | 30+3 | CS (1) | 0/1 | - | - | 0/1 | - |
|
| CR | 1 | 1 | 35+5 | CS (1) | 1/1 | 1/1 | 1/1 | 1/1 | 1/1 |
|
| CR | 1 | 1 | 40 | CS (1) | 1/1 | 0/1 | 0/1 | - | - |
|
| CR | 1 | 1 | 33 | VD (1) | 0/1 | - | - | 0/1 | 0/1 |
|
| RS | 116 | 100 | 37+3 – 39+4 | VD (14) | - | 0/10 | 0/10 | - | - |
|
| RS | 27 | 24 | 30-40 | VD (5) | 0/23 | - | - | - | IgG 1/1 |
|
| RS | 7 | 7 | 37-41+5 | CS (7) | 1/3 | - | - | - | - |
|
| CR | 1 | 1 | 32 | CS (1) | 0/1 | 0/1 | 0/1 | 1/1 | - |
|
| CaS | 6 | 6 | - | CS (6) | 0/6 | - | - | - | IgG 3/6 |
|
| PCS | 250 | 255 | 37-39 | VD (142) | 5/255 | - | - | - | - |
|
| CaS | 2 | 2 | 36-37 | CS (2) | 0/2 | 0/2 | 0/2 | 0/2 | - |
|
| CR | 1 | 1 | 34+3 | CS (1) | 0/1 | 0/1 | 0/1 | 0/1 | - |
|
| PCS | 30 | 31 | 20-36+1 | VD (5) | 0/31 | 0/31 | 0/31 | 0/31 | IgG – |
| i Gioia et al. 2022 | CR | 1 | 1 | 36+1 | VD (1) | 0/1 | 1/1 | - | - | - |
|
| CR | 1 | 2 | 32 | CS (1) | 1/2 | 1/2 | - | - | 0/2 |